Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: A cost-effectiveness analysis

Gut

Volumn 61, Issue 8, 2012, Pages 1172-1179

  Hassan, Cesare ^a   Rex, Douglas K ^b   Cooper, Gregory S ^c   Zullo, Angelo ^a   Launois, Robert ^d   Benamouzig, Robert ^e  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d REES France   (France)

^e AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLONOSCOPY; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SIGMOIDOSCOPY; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 84863726621     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300206     Document Type: Article

References (33)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92. (Pubitemid 46359643)
2. Micheli A, Mugno E, Krogh V, et al. Cancer prevalence in European registry areas. Ann Oncol 2002;13:840-65. (Pubitemid 34752680)
3. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
4. Benamouzig R, Uzzan B. Aspirin to prevent colorectal cancer: time to act? Lancet 2010;376:1713-14.
5. Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13. (Pubitemid 46710123)
6. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36. (Pubitemid 36929412)
7. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional nonaspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8. (Pubitemid 44893570)
8. Levin B, Lieberman DA, McFarland B, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-95. (Pubitemid 351615355)
9. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:638-58.
10. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol 2009;104:739-50.
11. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-33.
12. Brenner H, Chang-Claude J, Seiler CM, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011;154:22-30.
13. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1-8.
14. Lakoff J, Paszat LF, Saskin R, et al. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol 2008;6:1117-21.
15. Singh H, Nugent Z, Demers AA, et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 2010;139:1128-37.
16. Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:96-104. (Pubitemid 34779153)
17. Surveillance, Epidemiology and End Results. http://seer.cancer.gov/ faststats/ (accessed 15 Jan 2011).
18. http://www.census.gov. (accessed 15 Jan 2011).
19. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
20. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9. (Pubitemid 36297997)
21. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006;145:880-6. (Pubitemid 351639963)
22. http://www.cms.hhs.gov/pfslookup. (accessed 15 Sep 2008).
23. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index for all urban Consumers (CPI-U), U.S. City Average, Medical Care. http://www.bls.gov/cpi/home.htm. (accessed 14 Feb 2010).
24. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
25. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. (Pubitemid 36297996)
26. Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001;135:769-81. (Pubitemid 33051261)
27. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 2002;122:78-84. (Pubitemid 34049197)
28. Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-9. (Pubitemid 26299146)
29. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71. (Pubitemid 32973555)
30. Morant SV, McMahon AD, Cleland JG, et al. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004;57:188-98. (Pubitemid 38223531)
31. Singh H, Turner D, Xue L, et al. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 2006;295:2366-73. (Pubitemid 43788104)
32. Hewett DG, Kahi CJ, Rex DK. Efficacy and effectiveness of colonoscopy: how do we bridge the gap? Gastrointest Endosc Clin N Am 2010;20:673-84.
33. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010;362:1795-803.